Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • 100 percent Protection...

    100 percent Protection of Dettol leads to Court Battle

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2016-09-30T16:55:23+05:30  |  Updated On 16 Aug 2021 2:27 PM IST
    Reckitt Benckiser drags Advertising Standard Council Of India to Court against its recommendation opposing 100% germ protection Jargon

    New Delhi: One of the largest British consumer health goods maker, Reckitt Benckiser, has dragged the advertising standards council of India (ASCI) to Court against its recommendation opposing the jargon of RB's brand dettol "100% germ protection".

    The ASCI had passed a recommendation calling to take off the 'misleading' claims for the largest soap brand Dettol after receiving complaints from consumers. ASCI recommended that the Dettol's claim giving "100% better protection verses leading germ protection soap" was over exaggerated.

    The multinational firm is aggrieved by the ASCI recommendation has decided to approach the court

    "Aggrieved by ASCI's order on our Dettol bar soap television commercial which in our view was illegal procedurally and on merit, RB elected its legal remedies and approached the Hon'ble Delhi High Court seeking restraint of ASCI's order", stated Spokesperson of Reckitt Benckiser to ET.

    In contrast to the RB's contention, ASCI chairman Srinivasan Swamy said, "We are here to protect the interest of the consumer. We want advertisers to be truthful and substantiate what they say; we don't want consumers to be taken for a ride.The Hon'ble High Court after hearing our submissions and that of ASCI as they were in caveat, stayed its order and further restrained ASCI from taking any consequential steps in terms thereof."

    The Delhi High Court is yet to declare the final decision, though RB has got temporary stay. Whereby, both ASCI and RB spokespersons added they would not like to comment in further detail about the case since the matter is sub-judice before the court.
    100 percentASCIdettolgerm protectionReckitt Benckiser
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok